Skip to main content

Table 2 Otologic characteristics of patients with MEE (n = 23)

From: Intractable middle ear effusion in EGPA patients might cause permanent hearing loss: a case–control study

Characteristics Median (IQR) or No. (%)
Age at onset of ear symptoms, years 45 (35–65)
Time from EGPA diagnosis to ear symptoms, years 3.6 (1.0–7.9)
History of MEE before diagnosis 5 (21.7)
Maintenance steroid dose before ear symptoms
 Prednisolone ≥ 10 mg 4 (17.4)
 Prednisolone 5–10 mg 9 (39.1)
 Prednisolone < 5 mg 3 (13.0)
 None 7 (30.4)
Types of ear symptoma
 Ear fullness 16 (69.6)
 Hearing loss 12 (52.2)
 Tinnitus 7 (30.4)
 Otorrhea 6 (26.1)
 Otalgia 4 (17.4)
Severity of hearing loss (n = 15)
 Left
  Normalb 8 (53.3)
  Mild hearing loss 5 (33.3)
  Moderate hearing loss 2 (13.3)
 Right
  Normalb 6 (40.0)
  Mild hearing loss 5 (33.3)
  Moderate hearing loss 4 (26.7)
Type of hearing loss (n = 12)
 Conductive hearing loss 10 (83.3)
 Mixed hearing loss 2 (16.7)
Treatment regimen for MEE
 Myringotomy/VT insertion + IT injection + systemic steroid dose increase 7 (30.4%)
 Myringotomy/VT insertion + systemic steroid dose increase 3 (13.0%)
 IT injection + systemic steroid dose increase 1 (4.3%)
 Steroid dose increase 6 (26.1%)
 Myringotomy/VT insertion 3 (13.0%)
 No treatment 3 (13.0%)
Recurrence of the ear symptoms 9 (39.1)
  1. Data are presented as number (percentage) or median (interquartile range)
  2. EGPA, Eosinophilic granulomatosis with polyangiitis; IT, Intratympanic; MEE, Middle ear effusion; VT, Ventilation tube
  3. aSome patients complained of more than one symptom
  4. bFunctionally normal hearing classified based on PTA ≤ 15 dB